Acute Kidney Injury Associated with Severe SARS-CoV-2 Infection: Risk Factors for Morbidity and Mortality and a Potential Benefit of Combined Therapy with Tocilizumab and Corticosteroids.
Jose IglesiasAndrew VassalloJustin IlaganSong Peng AngNdausung UdongwoAnton MararenkoAbbas AlshamiDylon PatelYasmine ElbagaJerrold S LevinePublished in: Biomedicines (2023)
This study confirms the high rate of AKI and associated mortality among COVID-19 patients admitted to ICUs and suggests a role for inflammation and/or coagulopathy in AKI development. One should consider the possibility that early administration of anti-inflammatory agents, as is now routinely conducted in the management of COVID-19-associated acute respiratory distress syndrome, may improve clinical outcomes in patients with AKI.
Keyphrases
- acute kidney injury
- acute respiratory distress syndrome
- coronavirus disease
- cardiac surgery
- sars cov
- extracorporeal membrane oxygenation
- anti inflammatory
- mechanical ventilation
- respiratory syndrome coronavirus
- rheumatoid arthritis
- juvenile idiopathic arthritis
- type diabetes
- mesenchymal stem cells
- risk assessment
- risk factors
- drug induced
- cell therapy
- rheumatoid arthritis patients